We are in the midst of a ‘psychedelic renaissance’. Not since the 1950s and early 1960s has there been so much interest in researching the therapeutic potential of psychedelics. The FDA approved a ketamine derivative for medicinal use in 2019, and has given both MDMA and psilocybin (the psycho-active ingredient in magic mushrooms) ‘breakthrough therapy’ status, putting the drugs on a fast track to approval in the US, with the UK likely to follow suit.
Disagree with half of it, enjoy reading all of it
TRY 3 MONTHS FOR $5
Our magazine articles are for subscribers only. Start your 3-month trial today for just $5 and subscribe to more than one view
Already a subscriber? Log in
Comments
Join the debate for just £1 a month
Be part of the conversation with other Spectator readers by getting your first three months for £3.
UNLOCK ACCESS Just £1 a monthAlready a subscriber? Log in